Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies

Nuclear Medicine Communications

Volumn 28, Issue 7, 2007, Pages 547-553

  Nanni, Cristina ^a   Pettinato, Cinzia ^a   Ambrosini, Valentina ^a   Spinelli, Antonello ^a   Trespidi, Silvia ^b   Rubello, Domenico ^b   Al Nahhas, Adil ^b   Franchi, Roberto ^c   Alavi, Abass ^c   Fanti, Stefano ^c  

^a Unit of Nuclear Medicine   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Retro orbital injection; Route of administration; Small animal PET

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; IMAGE ANALYSIS; IMAGE QUALITY; INHALATION ANESTHESIA; INSTITUTE FOR CANCER RESEARCH MOUSE; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SLEEP INDUCTION;

ANIMALS; CARBON RADIOISOTOPES; CHOLINE; FEMALE; FLUORODEOXYGLUCOSE F18; IMAGE ENHANCEMENT; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 34249781398     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3281fbd42b     Document Type: Article

References (20)

1. Prenen H, Deroose C, Vermaelen P. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res 2006; 26(2A):1247-1252.
2. Barba J, Bastarrika G, Garcia Velloso MJ. Imaging modalities in cardiology: the present answers to permanent questions. Rev Med Univ Navarra 2005; 49:31-40.
3. Frangioni JV, Hajjar RJ. In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation 2004; 110:3378-3383.
4. Wyss MT, Honer M, Schubiger PA. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006; 33:311-318. Epub 2005, Oct 29.
5. 18F-FDG PET studies in mice. J Nucl Med 2006; 47:999-1006.
6. Wang Y, Seidel J, Tsui BM, Vaquero JJ, Pomper MG. Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med 2006; 47:1891-1900.
7. Vos FJ, Bleeker-Rovers CP, Corstens FH. FDG-PET for imaging of non-osseous infection and inflammation. Q J Nucl Med Mol Imaging 2006; 50:121-130.
8. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006; 47:1326-1334.
9. 18FDG PET in oncology: the best and the worst. Int J Oncol 2006; 28:1249-1261.
10. Saleem A, Charnley N, Price P. Clinical molecular imaging with positron emission tomography. Eur J Cancer 2006; 42:1720-1727.
11. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47:1059-1066.
12. Sanz G, Rioja J, Zudaire JJ. PET and prostate cancer. World J Urol 2004; 22:351-352.
13. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34:274-292.
14. 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006; 47:938-944.
15. 11C-choline PET. J Nucl Med 2003; 44:331-335.
16. 11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 2004; 12:2887-2893.
17. 11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. Nucl Med Biol 2002; 29:803-807.
18. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000; 27:731-743.
19. Kesner AL, Dahlbom M, Huang SC. Semiautomated analysis of small-animal PET data. J Nucl Med 2006; 47:1181-1186.
20. Yang H, Berger F, Tran C. MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. Prostate 2003; 55:39-47.